spec sheet10 rows
GDF-11, or growth differentiation factor 11 (also called bone morphogenetic protein 11), is a secreted signaling protein of the transforming growth factor beta (TGF-beta) superfamily. It is closely related to myostatin, sharing much of its structure and using the same receptors, and during embryonic development it helps pattern the skeleton and other tissues [1][5]. GDF-11 became widely known through contested research that proposed it as a blood-borne rejuvenation factor, a claim later studies called into question [2][5].
- Proposed tissue rejuvenation (disputed)
- Possible cardiac remodeling effects
- Research interest in neurogenesis
Overview
GDF-11 is a protein encoded by the GDF11 gene and secreted as a signaling molecule of the transforming growth factor beta superfamily, the large family that also includes the bone morphogenetic proteins and the activins. It is very closely related to myostatin, the muscle-limiting factor also known as GDF-8, sharing a high degree of sequence similarity in the active portion of the molecule and binding the same cell-surface receptors [5]. Like other members of its family, it is made as a precursor that is processed to release the mature, active protein.
The best-established role of GDF-11 is in embryonic development [1]. Studies in mice showed that it acts as a global signal specifying position along the head-to-tail axis of the body: animals lacking the gene develop with their vertebrae and ribs transformed toward more forward identities and with the hindlimbs displaced, changes accompanied by shifts in the activity of the Hox genes that lay out the body plan [1]. GDF-11 also takes part in the formation of the nervous system, the kidney, and other organs, and it influences the generation of certain nerve and retinal cells.
Beginning in 2013, GDF-11 drew intense attention when experiments using parabiosis, in which the circulations of a young and an old mouse are surgically joined, reported that a blood factor capable of reversing age-related changes was GDF-11, and that its level fell with age [2]. Follow-up papers extended the claim, describing improvements in aged skeletal muscle [3] and in the blood vessels and neurogenesis of the aging brain [4] when GDF-11 was restored. These findings generated wide interest in the protein as a possible anti-aging therapy.
The rejuvenation claims soon became controversial [5]. Other researchers reported that the assays used in the earlier work did not clearly distinguish GDF-11 from the very similar myostatin, and that with more specific measurements GDF-11 appeared to increase, rather than decrease, with age; in their experiments GDF-11 inhibited muscle regeneration instead of promoting it [5]. This contradiction has not been fully resolved, and the true direction and size of GDF-11's effects on aging tissues remain debated. Interest in manipulating the protein and its receptors nonetheless continues in research on conditions such as stroke and age-related muscle loss.
GDF-11 is a naturally occurring signaling protein rather than an approved medicine. Recombinant forms are used as research tools, and companies have pursued its therapeutic potential, but no GDF-11-based treatment is established in clinical practice. Because it shares receptors and downstream signaling with myostatin, work on GDF-11 is closely tied to the broader study of TGF-beta family proteins in muscle, heart, and nervous-system biology [5].
Mechanism
GDF-11 signals in the manner typical of the transforming growth factor beta superfamily [5]. The mature protein binds activin type II receptors (ActRIIA and ActRIIB) at the cell surface, which then recruit and activate type I receptors, chiefly the activin receptor-like kinases ALK4 and ALK5; the activated receptor complex phosphorylates the intracellular messengers SMAD2 and SMAD3, which partner with SMAD4 and move to the nucleus to regulate gene transcription [5]. Because GDF-11 and myostatin are so similar and converge on this same SMAD2/3 pathway, they produce overlapping effects on cells, including the inhibition of muscle-cell differentiation, a point central to the debate over GDF-11's role in aging [5].
During development, the same signaling is thought to act as a graded positional cue that sets Hox gene expression and thereby anterior-posterior identity along the axial skeleton [1]. The protein circulates bound to portions of its own precursor, which hold it in a latent state until it is activated, a layer of control that complicates measurement of the biologically active fraction and helped give rise to the conflicting reports about how its levels change with age [5]. Its downstream influence on cell growth, differentiation, and tissue maintenance is the basis for continuing interest in both stimulating and blocking the pathway in different tissues [2][5].
receptor fingerprint
Activin type II receptors (ActRIIA/B)agonist
SMAD2/3 pathwayactivates
Skeletal musclemay inhibit
Cardiac hypertrophymodulates
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
There is no established human safety profile for GDF-11 as a supplement. Given its myostatin-like signaling, chronic exposure could theoretically impair muscle and other tissues. Research-grade material sold online is unregulated and unverified, which is its own hazard.
Subjective profileweighing the evidence above
Fascinating research protein, but the anti-aging story is unresolved and possibly wrong. Not worth injecting on current evidence.
Resources
This entry is here for reference.
Research
- 1999first citedRegulation of anterior/posterior patterning of the axial skeleton by growth/differentiation fac…
- 2015most recentGDF11 increases with age and inhibits skeletal muscle regeneration
- 1.Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11
- 2.Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy
- 3.Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle
- 4.Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors
- 5.GDF11 increases with age and inhibits skeletal muscle regeneration
5 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Does GDF-11 reverse aging?
The early claims were exciting but later studies contradicted them, so the honest answer is we do not know.
Is it good for building muscle?
Probably not; it is closely related to myostatin, which limits muscle growth.
Do GDF-11 levels rise or fall with age?
Studies disagree, largely because early assays could not tell GDF-11 apart from GDF-8.
Is it safe to inject?
There is no human safety data and research-grade material is unverified, so using it is not advisable.
Why is it so controversial?
Because measurement errors and conflicting results turned a headline finding into an ongoing scientific argument.
Limitations of the evidence
- Its effects on aging tissues are scientifically debated
Notes and cautions
- A natural signaling protein studied mainly in research settings
- Shares receptors and actions with myostatin